cancer	3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
cancer	3493432	3558	Rosenberg SA	A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.	The New England journal of medicine	1987	221
cancer	6327821	3558	Weiss A	The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.	Journal of immunology	1984	179
cancer	7523571	3558	Carson WE	Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.	The Journal of experimental medicine	1994	200
cancer	8011282	3558	Romagnani S	Lymphokine production by human T cells in disease states.	Annual review of immunology	1994	169
cancer	8028037	3558	Rosenberg SA	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	Journal of the National Cancer Institute	1994	157
cancer	8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
cancer	9500606	3558	Rosenberg SA	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.	Nature medicine	1998	274
cancer	10358752	3558	Waldmann TA	The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.	Annual review of immunology	1999	139
cancer	10685652	3558	Atkins MB	High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.	The cancer journal from Scientific American	2000	117
cancer	10699311	3558	Sudimack J	Targeted drug delivery via the folate receptor.	Advanced drug delivery reviews	2000	117
cancer	10887096	3558	Kunzmann V	Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.	Blood	2000	98
cancer	11022927	3558	Takayama T	Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.	Lancet	2000	135
cancer	11357146	3558	Rosenberg SA	Progress in human tumour immunology and immunotherapy.	Nature	2001	236
cancer	11565838	3558	Dudley ME	Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.	Journal of immunotherapy	2001	108
cancer	12000866	3558	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	86
cancer	12082564	3558	Capuron L	Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.	Molecular psychiatry	2002	99
cancer	12427970	3558	Yee C	Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	320
cancer	12623838	3558	Wilhelm M	Gammadelta T cells for immune therapy of patients with lymphoid malignancies.	Blood	2003	109
cancer	12843795	3558	Dudley ME	Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.	Journal of immunotherapy	2003	157
cancer	12915604	3558	Yang JC	Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.	Journal of clinical oncology 	2003	110
cancer	14961035	3558	Imai C	Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.	Leukemia	2004	141
cancer	14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
cancer	15141157	3558	Nakamura K	Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.	Gene therapy	2004	141
cancer	15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
cancer	15638853	3558	Hayashi T	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.	British journal of haematology	2005	70
cancer	15674877	3558	Coppin C	Immunotherapy for advanced renal cell cancer.	The Cochrane database of systematic reviews	2005	88
cancer	15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
cancer	15897568	3558	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	68
cancer	15980149	3558	Klebanoff CA	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	231
cancer	16121185	3558	Watanabe N	Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.	Nature	2005	162
cancer	16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
cancer	16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
cancer	16364519	3558	Farag SS	Human natural killer cell development and biology.	Blood reviews	2006	79
cancer	16763205	3558	Banerjee DK	Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.	Blood	2006	94
cancer	17025272	3558	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	68
cancer	17075125	3558	Mackensen A	Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.	Journal of clinical oncology 	2006	92
cancer	17108138	3558	Kowolik CM	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.	Cancer research	2006	155
cancer	17671216	3558	Clayton A	Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.	Cancer research	2007	106
cancer	18000167	3558	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	73
cancer	18281670	3558	Testori A	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.	Journal of clinical oncology 	2008	69
cancer	18334676	3558	Ferrajoli A	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.	Blood	2008	105
cancer	18457330	3558	Klapper JA	High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.	Cancer	2008	60
cancer	18508251	3558	Curiel TJ	Regulatory T cells and treatment of cancer.	Current opinion in immunology	2008	66
cancer	18509084	3558	Till BG	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.	Blood	2008	185
cancer	18559587	3558	Bergmann C	T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease.	Clinical cancer research 	2008	56
cancer	18779745	3558	Tran KQ	Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.	Journal of immunotherapy	2008	61
cancer	18809613	3558	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	389
cancer	19001327	3558	Atkins MB	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.	Journal of clinical oncology 	2008	57
cancer	19265131	3558	Castriconi R	NK cells recognize and kill human glioblastoma cells with stem cell-like properties.	Journal of immunology	2009	54
cancer	19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
cancer	19383914	3558	Fujisaki H	Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.	Cancer research	2009	103
cancer	19465693	3558	Chung DJ	Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.	Blood	2009	83
cancer	19544689	3558	Bhatia S	Treatment of metastatic melanoma: an overview.	Oncology	2009	95
cancer	19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
cancer	20068175	3558	Schatton T	Modulation of T-cell activation by malignant melanoma initiating cells.	Cancer research	2010	66
cancer	20085940	3558	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	118
cancer	20304086	3558	Jensen MC	Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.	Biology of blood and marrow transplantation 	2010	119
cancer	20406835	3558	Besser MJ	Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.	Clinical cancer research 	2010	105
cancer	20439625	3558	Abès R	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.	Blood	2010	55
cancer	20491785	3558	Meraviglia S	In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.	Clinical and experimental immunology	2010	57
cancer	20557286	3558	Heller LC	Electroporation gene therapy preclinical and clinical trials for melanoma.	Current gene therapy	2010	41
cancer	20558731	3558	Mandapathil M	Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.	The Journal of biological chemistry	2010	47
cancer	20651070	3558	Görgün G	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.	Blood	2010	47
cancer	20668005	3558	Dudley ME	CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.	Clinical cancer research 	2010	60
cancer	20680271	3558	Bachanova V	Allogeneic natural killer cells for refractory lymphoma.	Cancer immunology, immunotherapy 	2010	46
cancer	20736326	3558	Jacobs JF	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.	Clinical cancer research 	2010	50
cancer	20849361	3558	Geller MA	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.	Cytotherapy	2011	84
cancer	20881001	3558	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	44
cancer	20921469	3558	Shusterman S	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.	Journal of clinical oncology 	2010	61
cancer	20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
cancer	20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
cancer	20978269	3558	Hsu AK	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.	Blood	2011	43
cancer	21212434	3558	Garbe C	Systematic review of medical treatment in melanoma: current status and future prospects.	The oncologist	2011	78
cancer	21389874	3558	Hernandez-Chacon JA	Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.	Journal of immunotherapy	2011	37
cancer	21498393	3558	Rosenberg SA	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.	Clinical cancer research 	2011	412
cancer	21631324	3558	Schwartzentruber DJ	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.	The New England journal of medicine	2011	208
cancer	21771874	3558	Lesterhuis WJ	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.	Clinical cancer research 	2011	39
cancer	21791425	3558	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	69
cancer	22129252	3558	Koreth J	Interleukin-2 and regulatory T cells in graft-versus-host disease.	The New England journal of medicine	2011	209
cancer	22160384	3558	Kochenderfer JN	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.	Blood	2012	345
cancer	22275504	3558	Liu L	Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.	Clinical cancer research 	2012	37
cancer	22311675	3558	Andersen RS	Dissection of T-cell antigen specificity in human melanoma.	Cancer research	2012	44
cancer	22393002	3558	Chapuis AG	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2012	47
cancer	22461638	3558	Rosenberg SA	Raising the bar: the curative potential of human cancer immunotherapy.	Science translational medicine	2012	75
cancer	22555974	3558	Yao X	Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.	Blood	2012	44
cancer	22674552	3558	Seung SK	Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.	Science translational medicine	2012	56
cancer	23369684	3558	Jang S	Which drug, and when, for patients with BRAF-mutant melanoma?	The Lancet. Oncology	2013	45
cancer	23552371	3558	Matsuoka K	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.	Science translational medicine	2013	93
cancer	23639322	3558	Lippitz BE	Cytokine patterns in patients with cancer: a systematic review.	The Lancet. Oncology	2013	136
cancer	23650429	3558	Dudley ME	Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.	Journal of clinical oncology 	2013	44
cancer	23741305	3558	Singh H	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.	PloS one	2013	39
cancer	23982524	3558	Kaufman HL	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.	Nature reviews. Clinical oncology	2013	37
cancer	24094496	3558	Tonn T	Treatment of patients with advanced cancer with the natural killer cell line NK-92.	Cytotherapy	2013	40
cancer	24573552	3558	Kennedy-Nasser AA	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.	Clinical cancer research 	2014	32
cancer	24577748	3558	Ackerman A	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.	Cancer	2014	29
cancer	24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
cancer	24782509	3558	Xu Y	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.	Blood	2014	59
cancer	24907378	3558	Rosenberg SA	IL-2: the first effective immunotherapy for human cancer.	Journal of immunology	2014	84
cancer	25060490	3558	McDermott D	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.	Cancer treatment reviews	2014	37
cancer	25415285	3558	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	24
cancer	25503054	3558	Schuetz A	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.	PLoS pathogens	2014	48
cancer	25695689	3558	Zhang L	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.	Clinical cancer research 	2015	29
cancer	25747273	3558	Lee JH	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	31
cancer	25850950	3558	Katz SC	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.	Clinical cancer research 	2015	23
cancer	25940712	3558	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	25
cancer	27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
glycoproteins	6975347	3558	Robb RJ	T cell growth factor receptors. Quantitation, specificity, and biological relevance.	The Journal of experimental medicine	1981	224
glycoproteins	7523571	3558	Carson WE	Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.	The Journal of experimental medicine	1994	200
glycoproteins	9500606	3558	Rosenberg SA	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.	Nature medicine	1998	274
glycoproteins	10699311	3558	Sudimack J	Targeted drug delivery via the folate receptor.	Advanced drug delivery reviews	2000	117
glycoproteins	11565838	3558	Dudley ME	Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.	Journal of immunotherapy	2001	108
glycoproteins	11675346	3558	Ng WF	Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.	Blood	2001	100
glycoproteins	12427970	3558	Yee C	Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	320
glycoproteins	12480696	3558	Fehniger TA	CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.	Blood	2003	179
glycoproteins	12843795	3558	Dudley ME	Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.	Journal of immunotherapy	2003	157
glycoproteins	15218108	3558	Sivori S	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	87
glycoproteins	15780987	3558	Freud AG	A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.	Immunity	2005	99
glycoproteins	16007258	3558	Valmori D	A peripheral circulating compartment of natural naive CD4 Tregs.	The Journal of clinical investigation	2005	96
glycoproteins	16051844	3558	Brooks DG	Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.	Journal of virology	2005	82
glycoproteins	16121185	3558	Watanabe N	Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.	Nature	2005	162
glycoproteins	16567385	3558	Jabbari A	Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype.	The Journal of experimental medicine	2006	83
glycoproteins	17025272	3558	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	68
glycoproteins	19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
glycoproteins	20491785	3558	Meraviglia S	In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.	Clinical and experimental immunology	2010	57
glycoproteins	20736326	3558	Jacobs JF	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.	Clinical cancer research 	2010	50
glycoproteins	20921469	3558	Shusterman S	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.	Journal of clinical oncology 	2010	61
glycoproteins	20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
glycoproteins	20951793	3558	Janelidze S	Cytokine levels in the blood may distinguish suicide attempters from depressed patients.	Brain, behavior, and immunity	2011	44
glycoproteins	21521467	3558	Thompson P	CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates.	American journal of transplantation 	2011	39
glycoproteins	21771874	3558	Lesterhuis WJ	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.	Clinical cancer research 	2011	39
immune+or+immune+system	1846244	3558	Fraser JD	Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.	Science	1991	152
immune+or+immune+system	2871125	3558	Kehrl JH	Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.	The Journal of experimental medicine	1986	304
immune+or+immune+system	2995487	3558	McDougal JS	Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.	Journal of immunology	1985	169
immune+or+immune+system	3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
immune+or+immune+system	6327821	3558	Weiss A	The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.	Journal of immunology	1984	179
immune+or+immune+system	6975347	3558	Robb RJ	T cell growth factor receptors. Quantitation, specificity, and biological relevance.	The Journal of experimental medicine	1981	224
immune+or+immune+system	7523571	3558	Carson WE	Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.	The Journal of experimental medicine	1994	200
immune+or+immune+system	8028037	3558	Rosenberg SA	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	Journal of the National Cancer Institute	1994	157
immune+or+immune+system	8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
immune+or+immune+system	8691133	3558	Groux H	Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.	The Journal of experimental medicine	1996	137
immune+or+immune+system	10358752	3558	Waldmann TA	The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.	Annual review of immunology	1999	139
immune+or+immune+system	10371503	3558	Chun TW	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.	Nature medicine	1999	122
immune+or+immune+system	10611346	3558	Davey RT Jr	HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.	Proceedings of the National Academy of Sciences of the United States of America	1999	198
immune+or+immune+system	10887096	3558	Kunzmann V	Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.	Blood	2000	98
immune+or+immune+system	11081504	3558	Parrish-Novak J	Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.	Nature	2000	237
immune+or+immune+system	11357146	3558	Rosenberg SA	Progress in human tumour immunology and immunotherapy.	Nature	2001	236
immune+or+immune+system	11565838	3558	Dudley ME	Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.	Journal of immunotherapy	2001	108
immune+or+immune+system	11675346	3558	Ng WF	Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.	Blood	2001	100
immune+or+immune+system	12000866	3558	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	86
immune+or+immune+system	12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
immune+or+immune+system	12427970	3558	Yee C	Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	320
immune+or+immune+system	12480696	3558	Fehniger TA	CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.	Blood	2003	179
immune+or+immune+system	12623838	3558	Wilhelm M	Gammadelta T cells for immune therapy of patients with lymphoid malignancies.	Blood	2003	109
immune+or+immune+system	12663797	3558	Wherry EJ	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.	Journal of virology	2003	484
immune+or+immune+system	12843795	3558	Dudley ME	Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.	Journal of immunotherapy	2003	157
immune+or+immune+system	14961035	3558	Imai C	Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.	Leukemia	2004	141
immune+or+immune+system	15100259	3558	Zheng SG	Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10.	Journal of immunology	2004	148
immune+or+immune+system	15128946	3558	Sundrud MS	Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
immune+or+immune+system	15218108	3558	Sivori S	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	87
immune+or+immune+system	15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
immune+or+immune+system	15638853	3558	Hayashi T	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.	British journal of haematology	2005	70
immune+or+immune+system	15777785	3558	Rasmusson I	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.	Experimental cell research	2005	91
immune+or+immune+system	15780987	3558	Freud AG	A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.	Immunity	2005	99
immune+or+immune+system	15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
immune+or+immune+system	15972602	3558	Wikby A	An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans.	The journals of gerontology. Series A, Biological sciences and medical sciences	2005	83
immune+or+immune+system	15980149	3558	Klebanoff CA	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	231
immune+or+immune+system	16007258	3558	Valmori D	A peripheral circulating compartment of natural naive CD4 Tregs.	The Journal of clinical investigation	2005	96
immune+or+immune+system	16051844	3558	Brooks DG	Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.	Journal of virology	2005	82
immune+or+immune+system	16121185	3558	Watanabe N	Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.	Nature	2005	162
immune+or+immune+system	16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
immune+or+immune+system	16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
immune+or+immune+system	16364519	3558	Farag SS	Human natural killer cell development and biology.	Blood reviews	2006	79
immune+or+immune+system	16567385	3558	Jabbari A	Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype.	The Journal of experimental medicine	2006	83
immune+or+immune+system	16763205	3558	Banerjee DK	Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.	Blood	2006	94
immune+or+immune+system	17075125	3558	Mackensen A	Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.	Journal of clinical oncology 	2006	92
immune+or+immune+system	17108138	3558	Kowolik CM	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.	Cancer research	2006	155
immune+or+immune+system	17110377	3558	Stopak KS	Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.	The Journal of biological chemistry	2007	75
immune+or+immune+system	17202333	3558	Peluso I	IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes.	Journal of immunology	2007	71
immune+or+immune+system	17289812	3558	Biancotto A	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.	Blood	2007	87
immune+or+immune+system	17671216	3558	Clayton A	Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.	Cancer research	2007	106
immune+or+immune+system	18334676	3558	Ferrajoli A	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.	Blood	2008	105
immune+or+immune+system	18508251	3558	Curiel TJ	Regulatory T cells and treatment of cancer.	Current opinion in immunology	2008	66
immune+or+immune+system	18509084	3558	Till BG	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.	Blood	2008	185
immune+or+immune+system	18559587	3558	Bergmann C	T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease.	Clinical cancer research 	2008	56
immune+or+immune+system	18684212	3558	Chang L	Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome.	Neurogastroenterology and motility 	2009	51
immune+or+immune+system	18779745	3558	Tran KQ	Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.	Journal of immunotherapy	2008	61
immune+or+immune+system	18809613	3558	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	389
immune+or+immune+system	19265131	3558	Castriconi R	NK cells recognize and kill human glioblastoma cells with stem cell-like properties.	Journal of immunology	2009	54
immune+or+immune+system	19383914	3558	Fujisaki H	Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.	Cancer research	2009	103
immune+or+immune+system	19404981	3558	Pinna D	Clonal dissection of the human memory B-cell repertoire following infection and vaccination.	European journal of immunology	2009	49
immune+or+immune+system	19465693	3558	Chung DJ	Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.	Blood	2009	83
immune+or+immune+system	19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
immune+or+immune+system	19933795	3558	Hopkins S	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.	Antimicrobial agents and chemotherapy	2010	41
immune+or+immune+system	19965651	3558	Curtale G	An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes.	Blood	2010	92
immune+or+immune+system	20085940	3558	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	118
immune+or+immune+system	20221423	3558	Makedonas G	Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.	PLoS pathogens	2010	56
immune+or+immune+system	20304086	3558	Jensen MC	Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.	Biology of blood and marrow transplantation 	2010	119
immune+or+immune+system	20382097	3558	Coura JR	Chagas disease: 100 years after its discovery. A systemic review.	Acta tropica	2010	42
immune+or+immune+system	20406835	3558	Besser MJ	Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.	Clinical cancer research 	2010	105
immune+or+immune+system	20439625	3558	Abès R	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.	Blood	2010	55
immune+or+immune+system	20491785	3558	Meraviglia S	In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.	Clinical and experimental immunology	2010	57
immune+or+immune+system	20558731	3558	Mandapathil M	Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.	The Journal of biological chemistry	2010	47
immune+or+immune+system	20651070	3558	Görgün G	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.	Blood	2010	47
immune+or+immune+system	20668005	3558	Dudley ME	CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.	Clinical cancer research 	2010	60
immune+or+immune+system	20680271	3558	Bachanova V	Allogeneic natural killer cells for refractory lymphoma.	Cancer immunology, immunotherapy 	2010	46
immune+or+immune+system	20736326	3558	Jacobs JF	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.	Clinical cancer research 	2010	50
immune+or+immune+system	20849361	3558	Geller MA	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.	Cytotherapy	2011	84
immune+or+immune+system	20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
immune+or+immune+system	20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
immune+or+immune+system	20978269	3558	Hsu AK	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.	Blood	2011	43
immune+or+immune+system	21278738	3558	Yang XP	Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.	Nature immunology	2011	191
immune+or+immune+system	21389874	3558	Hernandez-Chacon JA	Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.	Journal of immunotherapy	2011	37
immune+or+immune+system	21498393	3558	Rosenberg SA	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.	Clinical cancer research 	2011	412
immune+or+immune+system	21532597	3558	Wuest SC	A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.	Nature medicine	2011	76
immune+or+immune+system	21631324	3558	Schwartzentruber DJ	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.	The New England journal of medicine	2011	208
immune+or+immune+system	21771874	3558	Lesterhuis WJ	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.	Clinical cancer research 	2011	39
immune+or+immune+system	21791425	3558	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	69
immune+or+immune+system	21889323	3558	Liao W	IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation.	Current opinion in immunology	2011	102
immune+or+immune+system	21998698	3558	Olotu A	Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.	PloS one	2011	38
immune+or+immune+system	22072753	3558	Lachmann R	Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses.	Journal of virology	2012	33
immune+or+immune+system	22129252	3558	Koreth J	Interleukin-2 and regulatory T cells in graft-versus-host disease.	The New England journal of medicine	2011	209
immune+or+immune+system	22129253	3558	Saadoun D	Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.	The New England journal of medicine	2011	142
immune+or+immune+system	22160384	3558	Kochenderfer JN	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.	Blood	2012	345
immune+or+immune+system	22275504	3558	Liu L	Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.	Clinical cancer research 	2012	37
immune+or+immune+system	22311675	3558	Andersen RS	Dissection of T-cell antigen specificity in human melanoma.	Cancer research	2012	44
immune+or+immune+system	22393002	3558	Chapuis AG	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2012	47
immune+or+immune+system	22453018	3558	Wu R	Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.	Cancer journal	2012	39
immune+or+immune+system	22461703	3558	Garg G	Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.	Journal of immunology	2012	43
immune+or+immune+system	22555974	3558	Yao X	Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.	Blood	2012	44
immune+or+immune+system	22674552	3558	Seung SK	Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.	Science translational medicine	2012	56
immune+or+immune+system	22706088	3558	Moorman JP	Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.	Journal of immunology	2012	32
immune+or+immune+system	22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
immune+or+immune+system	22737606	3558	Galluzzi L	Trial Watch: Adoptive cell transfer immunotherapy.	Oncoimmunology	2012	44
immune+or+immune+system	23552371	3558	Matsuoka K	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.	Science translational medicine	2013	93
immune+or+immune+system	23583734	3558	Hirschfield GM	The genetics of complex cholestatic disorders.	Gastroenterology	2013	28
immune+or+immune+system	23639322	3558	Lippitz BE	Cytokine patterns in patients with cancer: a systematic review.	The Lancet. Oncology	2013	136
immune+or+immune+system	23650429	3558	Dudley ME	Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.	Journal of clinical oncology 	2013	44
immune+or+immune+system	23741305	3558	Singh H	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.	PloS one	2013	39
immune+or+immune+system	24094496	3558	Tonn T	Treatment of patients with advanced cancer with the natural killer cell line NK-92.	Cytotherapy	2013	40
immune+or+immune+system	24573552	3558	Kennedy-Nasser AA	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.	Clinical cancer research 	2014	32
immune+or+immune+system	24622415	3558	Hartemann A	Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.	The lancet. Diabetes and endocrinology	2013	45
immune+or+immune+system	24650034	3558	Kimbrel EA	Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties.	Stem cells and development	2014	28
immune+or+immune+system	24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
immune+or+immune+system	24782509	3558	Xu Y	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.	Blood	2014	59
immune+or+immune+system	24907378	3558	Rosenberg SA	IL-2: the first effective immunotherapy for human cancer.	Journal of immunology	2014	84
immune+or+immune+system	25171868	3558	Bartemes KR	Enhanced innate type 2 immune response in peripheral blood from patients with asthma.	The Journal of allergy and clinical immunology	2014	40
immune+or+immune+system	25415285	3558	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	24
immune+or+immune+system	25503054	3558	Schuetz A	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.	PLoS pathogens	2014	48
immune+or+immune+system	25576057	3558	Yu A	Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.	Diabetes	2015	21
immune+or+immune+system	25695689	3558	Zhang L	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.	Clinical cancer research 	2015	29
immune+or+immune+system	25747273	3558	Lee JH	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	31
immune+or+immune+system	25850950	3558	Katz SC	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.	Clinical cancer research 	2015	23
immune+or+immune+system	25939024	3558	Thiault N	Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors.	Nature immunology	2015	23
immune+or+immune+system	25940712	3558	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	25
immune+or+immune+system	26324847	3558	von Spee-Mayer C	Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.	Annals of the rheumatic diseases	2016	12
immune+or+immune+system	27006492	3558	Andersen R	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.	Clinical cancer research 	2016	16
immune+or+immune+system	27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
immune+or+immune+system	27500725	3558	He J	Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.	Nature medicine	2016	11
infectious+or+infection	2995487	3558	McDougal JS	Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.	Journal of immunology	1985	169
infectious+or+infection	8011282	3558	Romagnani S	Lymphokine production by human T cells in disease states.	Annual review of immunology	1994	169
infectious+or+infection	10358758	3558	Lenardo M	Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.	Annual review of immunology	1999	192
infectious+or+infection	10371503	3558	Chun TW	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.	Nature medicine	1999	122
infectious+or+infection	10611346	3558	Davey RT Jr	HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.	Proceedings of the National Academy of Sciences of the United States of America	1999	198
infectious+or+infection	12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
infectious+or+infection	12663797	3558	Wherry EJ	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.	Journal of virology	2003	484
infectious+or+infection	15128946	3558	Sundrud MS	Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
infectious+or+infection	15141157	3558	Nakamura K	Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.	Gene therapy	2004	141
infectious+or+infection	15218108	3558	Sivori S	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	87
infectious+or+infection	15972602	3558	Wikby A	An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans.	The journals of gerontology. Series A, Biological sciences and medical sciences	2005	83
infectious+or+infection	15980149	3558	Klebanoff CA	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	231
infectious+or+infection	16051844	3558	Brooks DG	Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.	Journal of virology	2005	82
infectious+or+infection	17093248	3558	Brennan DC	Rabbit antithymocyte globulin versus basiliximab in renal transplantation.	The New England journal of medicine	2006	77
infectious+or+infection	17110377	3558	Stopak KS	Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.	The Journal of biological chemistry	2007	75
infectious+or+infection	17289812	3558	Biancotto A	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.	Blood	2007	87
infectious+or+infection	19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
infectious+or+infection	19404981	3558	Pinna D	Clonal dissection of the human memory B-cell repertoire following infection and vaccination.	European journal of immunology	2009	49
infectious+or+infection	19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
infectious+or+infection	19828532	3558	INSIGHT-ESPRIT Study Group.	Interleukin-2 therapy in patients with HIV infection.	The New England journal of medicine	2009	135
infectious+or+infection	20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
infectious+or+infection	22072753	3558	Lachmann R	Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses.	Journal of virology	2012	33
infectious+or+infection	22129253	3558	Saadoun D	Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.	The New England journal of medicine	2011	142
infectious+or+infection	22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
infectious+or+infection	22706088	3558	Moorman JP	Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.	Journal of immunology	2012	32
infectious+or+infection	22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
infectious+or+infection	25503054	3558	Schuetz A	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.	PLoS pathogens	2014	48
infectious+or+infection	26444729	3558	Kappos L	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.	The New England journal of medicine	2015	26
infectious+or+infection	27500725	3558	He J	Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.	Nature medicine	2016	11
kidney+or+urine	8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
kidney+or+urine	11357146	3558	Rosenberg SA	Progress in human tumour immunology and immunotherapy.	Nature	2001	236
kidney+or+urine	12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
kidney+or+urine	12915604	3558	Yang JC	Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.	Journal of clinical oncology 	2003	110
kidney+or+urine	14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
kidney+or+urine	15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
kidney+or+urine	15674877	3558	Coppin C	Immunotherapy for advanced renal cell cancer.	The Cochrane database of systematic reviews	2005	88
kidney+or+urine	15897568	3558	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	68
kidney+or+urine	16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
kidney+or+urine	16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
kidney+or+urine	17093248	3558	Brennan DC	Rabbit antithymocyte globulin versus basiliximab in renal transplantation.	The New England journal of medicine	2006	77
kidney+or+urine	19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
kidney+or+urine	20881001	3558	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	44
kidney+or+urine	22275504	3558	Liu L	Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.	Clinical cancer research 	2012	37
kidney+or+urine	22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
kidney+or+urine	22674552	3558	Seung SK	Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.	Science translational medicine	2012	56
kidney+or+urine	24907378	3558	Rosenberg SA	IL-2: the first effective immunotherapy for human cancer.	Journal of immunology	2014	84
liver+or+hepatic	3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
liver+or+hepatic	11022927	3558	Takayama T	Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.	Lancet	2000	135
liver+or+hepatic	12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
liver+or+hepatic	12663797	3558	Wherry EJ	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.	Journal of virology	2003	484
liver+or+hepatic	14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
liver+or+hepatic	15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
liver+or+hepatic	19933795	3558	Hopkins S	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.	Antimicrobial agents and chemotherapy	2010	41
liver+or+hepatic	21940902	3558	Bajaj JS	Linkage of gut microbiome with cognition in hepatic encephalopathy.	American journal of physiology. Gastrointestinal and liver physiology	2012	69
liver+or+hepatic	22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
liver+or+hepatic	23583734	3558	Hirschfield GM	The genetics of complex cholestatic disorders.	Gastroenterology	2013	28
liver+or+hepatic	25695689	3558	Zhang L	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.	Clinical cancer research 	2015	29
liver+or+hepatic	25747273	3558	Lee JH	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	31
liver+or+hepatic	25850950	3558	Katz SC	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.	Clinical cancer research 	2015	23
liver+or+hepatic	26444729	3558	Kappos L	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.	The New England journal of medicine	2015	26
liver+or+hepatic	27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	3493432	3558	Rosenberg SA	A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.	The New England journal of medicine	1987	221
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	8028037	3558	Rosenberg SA	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	Journal of the National Cancer Institute	1994	157
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	11675346	3558	Ng WF	Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.	Blood	2001	100
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	12000866	3558	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	86
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	16121185	3558	Watanabe N	Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.	Nature	2005	162
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	17289812	3558	Biancotto A	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.	Blood	2007	87
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	18000167	3558	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	73
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	18457330	3558	Klapper JA	High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.	Cancer	2008	60
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	18809613	3558	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	389
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	20085940	3558	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	118
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	20542324	3558	Blumchen K	Oral peanut immunotherapy in children with peanut anaphylaxis.	The Journal of allergy and clinical immunology	2010	70
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	20881001	3558	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	44
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	20921469	3558	Shusterman S	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.	Journal of clinical oncology 	2010	61
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	21498393	3558	Rosenberg SA	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.	Clinical cancer research 	2011	412
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	21998698	3558	Olotu A	Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.	PloS one	2011	38
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	23562009	3558	Gold R	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.	Lancet	2013	55
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	23650429	3558	Dudley ME	Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.	Journal of clinical oncology 	2013	44
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	23741305	3558	Singh H	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.	PloS one	2013	39
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	24094496	3558	Tonn T	Treatment of patients with advanced cancer with the natural killer cell line NK-92.	Cytotherapy	2013	40
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	24573552	3558	Kennedy-Nasser AA	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.	Clinical cancer research 	2014	32
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	24782509	3558	Xu Y	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.	Blood	2014	59
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	25415285	3558	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	24
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	25939024	3558	Thiault N	Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors.	Nature immunology	2015	23
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	25940712	3558	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	25
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
pediatric+or+newborn+or+infant+or+toddler+or+child+or+adolescent	27500725	3558	He J	Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.	Nature medicine	2016	11
stem+cells	15141157	3558	Nakamura K	Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.	Gene therapy	2004	141
stem+cells	15777785	3558	Rasmusson I	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.	Experimental cell research	2005	91
stem+cells	15780987	3558	Freud AG	A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.	Immunity	2005	99
stem+cells	19265131	3558	Castriconi R	NK cells recognize and kill human glioblastoma cells with stem cell-like properties.	Journal of immunology	2009	54
stem+cells	20304086	3558	Jensen MC	Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.	Biology of blood and marrow transplantation 	2010	119
stem+cells	20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
stem+cells	20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
stem+cells	21791425	3558	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	69
stem+cells	22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
stem+cells	23552371	3558	Matsuoka K	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.	Science translational medicine	2013	93
stem+cells	23741305	3558	Singh H	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.	PloS one	2013	39
stem+cells	24573552	3558	Kennedy-Nasser AA	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.	Clinical cancer research 	2014	32
stem+cells	24650034	3558	Kimbrel EA	Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties.	Stem cells and development	2014	28
stem+cells	24782509	3558	Xu Y	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.	Blood	2014	59
stem+cells	25939024	3558	Thiault N	Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors.	Nature immunology	2015	23
toxicology+or+toxic+or+toxin	3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
toxicology+or+toxic+or+toxin	15128946	3558	Sundrud MS	Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
toxicology+or+toxic+or+toxin	16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
toxicology+or+toxic+or+toxin	16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
toxicology+or+toxic+or+toxin	17025272	3558	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	68
toxicology+or+toxic+or+toxin	19001327	3558	Atkins MB	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.	Journal of clinical oncology 	2008	57
toxicology+or+toxic+or+toxin	21631324	3558	Schwartzentruber DJ	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.	The New England journal of medicine	2011	208
toxicology+or+toxic+or+toxin	21940902	3558	Bajaj JS	Linkage of gut microbiome with cognition in hepatic encephalopathy.	American journal of physiology. Gastrointestinal and liver physiology	2012	69
toxicology+or+toxic+or+toxin	22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
toxicology+or+toxic+or+toxin	24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
